Oliver Hasler, executive chairman of PYX Resources, presents 1H24 Results. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.40
Bid: 20.20
Ask: 22.00
Change: 0.00 (0.00%)
Spread: 1.80 (8.911%)
Open: 20.20
High: 20.40
Low: 20.20
Prev. Close: 21.10

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

9 Sep 2024 11:42

Oncimmune expects "substantial" revenue growth following contract wins

(Alliance News) - Oncimmune Holdings PLC said on Monday that it has entered into five new contracts since its last update in May this year, which are set to substantially grow revenue for financial 2025.

Read more
2 Sep 2024 17:35

Oncimmune Holdings agrees new contract valued at USD700,000

(Alliance News) - Oncimmune Holdings PLC announced on Monday that it has won a new contract with a top 10 global pharma company, for a project focused on a rare immune-related disease.

Read more
2 Sep 2024 10:13

Oncimmune secures additional contract with 'top ten global pharma' firm

(Sharecast News) - Biotechnology firm Oncimmune said on Monday that it had secured an additional contract with a "top ten global pharma company" worth $700,000.

Read more
9 Aug 2024 17:15

TRADING UPDATES: Tan Delta signs contract; Earnz loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Friday and not separately reported by Alliance News:

Read more
9 Aug 2024 11:21

AIM WINNERS & LOSERS: Hummingbird falls on mining challenges

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

Read more
9 Aug 2024 09:59

Oncimmune secures new contract win with 'top ten' global pharma company

(Sharecast News) - Autoantibody profiling business Oncimmune said on Friday that it had secured a new contract win with a "top ten global pharma company".

Read more
21 May 2024 16:27

EARNINGS AND TRADING: Topps Tiles in strategic shift as swings to loss

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
29 Feb 2024 17:00

EARNINGS: Leeds awaiting Hemmers sale, Macfarlane ups full-year payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Feb 2024 13:04

Oncimmune revenue falls as it implements new strategy

(Sharecast News) - Oncimmune reported revenue of £2.1m in its final results on Thursday, down from £3.8m for the prior extended 15-month period, with revenue from continuing operations totalling £1.2m.

Read more
19 Feb 2024 12:54

UK shareholder meetings calendar - next 7 days

Tuesday 20 February 
abrdn Equity Income Trust PLCAGM
Carr's Group PLCAGM
Dewhurst Group PLCAGM
Duke Royalty LtdEGM re changing name to Duke Capital
Wednesday 21 February 
Foresight Sustainable Forestry Co PLCAGM
Gooch & Housego PLCAGM
Tharisa PLCAGM
Thursday 22 February 
Bankers Investment Trust PLCAGM
Narf Industries PLCAGM
RWS Holdings PLCAGM
Sunrise Resources PLCAGM
Friday 23 February 
Blencowe Resources PLCAGM
Bluebird Merchant Ventures LtdAGM
Caledonian Trust PLCAGM
Chemring Group PLCAGM
Marble Point Loan Financing LtdEGM
Monday 26 February 
Oncimmune Holdings PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
30 Nov 2023 14:25

TRADING UPDATES: SkinBio launches food supplement on Amazon

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Oct 2023 14:21

IN BRIEF: Oncimmune shares jump following new strategy update

Oncimmune Holdings PLC - Nottingham, England-based immunodiagnostics developer - Announces plans to focus on higher value customers, penetrating key accounts, partnering with key technology suppliers and launching new tools. Intends to accelerate new commercial contracts through partnerships with more contract research organisations to expand customer base, leverage auto-antibody analysis capabilities across new areas like companion diagnostics, and augment its commercial team. Also plans to expand its business models "beyond price-per-sample to more strategic partnership models" with upfront project and milestone success fees to better reflect its value. Update follows the disposal of Oncimmune Ltd in May, and the hiring of Martin Gouldstone as chief executive officer and Martin Hudson as finance director in August and September respectively. Company says final results for year ended August 31 will be released in due course.

Read more
12 Jul 2023 11:14

Oncimmune names chief executive successor, while finance chief leaves

(Alliance News) - Oncimmune Holdings PLC on Wednesday said it appointed Martin Gouldstone as its new chief executive, replacing Adam Hill who stepped down following the divestment of Oncimmune Ltd.

Read more
23 Jun 2023 12:08

Oncimmune Holdings shakes up leadership and unveils new growth plan

(Alliance News) - Oncimmune Holdings PLC on Friday said its chief executive officer will step down, as it unveiled a new plan for delivering refocused growth.

Read more
31 May 2023 13:31

Oncimmune shares plummet as interim revenue falls by fifth

(Alliance News) - Oncimmune Holdings PLC on Wednesday said revenue was down in the first half of its financial year due to delivery delays, but its loss narrowed.

Read more

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.